ALDX
HEALTHCAREAldeyra The
AI Insight
What's Moving ALDX Today?
No stock-specific AI insight has been generated for ALDX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.07$6.17
$2.02
Fundamentals
Market Cap$118M
P/E Ratio—
EPS$-0.45
Dividend Yield—
Dividend / Share—
ROE-51.8%
Profit Margin—
Debt / Equity—
Trading
Volume2.4M
Avg Volume (10D)—
Shares Outstanding60.3M
ALDX News
49 articles- CEO, President & Director of Aldeyra Therapeutics Picks Up 18% More StockYahoo Finance·Jun 10, 2026
- Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of DirectorsYahoo Finance·Jun 10, 2026
- Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break MomentMarketbeat·Jun 5, 2026
- 3 Promising Penny Stocks With Market Caps Reaching $300MYahoo Finance·Jun 4, 2026
- Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare ConferenceYahoo Finance·Jun 2, 2026
- ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmGlobeNewswire·May 25, 2026
- Portnoy Law Firm Announces Class Action on Behalf of Aldeyra Therapeutics, Inc. InvestorsGlobeNewswire·May 19, 2026
- ALDX DEADLINE: The Gross Law Firm Reminds Aldeyra Therapeutics, Inc. Investors of Upcoming Securities Class Action DeadlineMorningstar·May 19, 2026
- Upstart Holdings Leads These 3 Stocks Estimated To Be Trading Below Fair ValueYahoo Finance·May 15, 2026
- 3 Stocks That May Be Undervalued According To Analysts In May 2026Yahoo Finance·May 15, 2026
- Pleasing Signs As A Number Of Insiders Buy Aldeyra Therapeutics StockYahoo Finance·May 5, 2026
- Extreme Networks And 2 Additional Stocks Estimated To Be Trading Below Their Fair ValueYahoo Finance·May 1, 2026
- Discover 3 Stocks That Might Be Trading Below Estimated ValueYahoo Finance·May 1, 2026
- 3 Stocks Estimated To Be Trading Below Intrinsic Value By Up To 35.4%Yahoo Finance·Apr 29, 2026
- 3 Stocks That May Be Trading Below Their Estimated Value In April 2026Yahoo Finance·Apr 29, 2026
- April 2026's Top 3 Stocks That May Be Trading Below Estimated Fair ValueYahoo Finance·Apr 27, 2026
- 3 Stocks That Might Be Undervalued By Up To 32.8%Yahoo Finance·Apr 27, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 26, 2026
- ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDXGlobeNewswire Inc.·Apr 25, 2026
- ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Coty Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – COTYGlobeNewswire Inc.·Apr 25, 2026
- ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDXGlobeNewswire Inc.·Apr 21, 2026
- ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Trip.com Group Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TCOMGlobeNewswire Inc.·Apr 21, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 19, 2026
- ROSEN, THE FIRST FILING FIRM, Encourages Lufax Holding Ltd Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - LUGlobeNewswire Inc.·Apr 18, 2026
- ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDXGlobeNewswire Inc.·Apr 18, 2026
- Bragar Eagel & Squire, P.C. Encourages Aldeyra Therapeutics, Inc. Investors to Contact the Firm Regarding Their RightsGlobeNewswire Inc.·Apr 15, 2026
- ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Omitted Inconsistent Trial Data: Levi & KorsinskyGlobeNewswire Inc.·Apr 13, 2026
- ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDXGlobeNewswire Inc.·Apr 12, 2026
- ROSEN, THE FIRST FILING FIRM, Encourages Trip.com Group Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TCOMGlobeNewswire Inc.·Apr 12, 2026
- ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmGlobeNewswire Inc.·Apr 10, 2026
- 3 Stocks That May Be Undervalued By Up To 48.1% According To Intrinsic Value EstimatesYahoo Finance·Apr 10, 2026
- 3 Stocks Possibly Undervalued By Up To 47% Offering Potential ValueYahoo Finance·Apr 10, 2026
- ROSEN, A LEADING AND RANKED FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDXGlobeNewswire Inc.·Apr 9, 2026
- 3 Stocks That May Be Trading Below Their Estimated Intrinsic ValueYahoo Finance·Apr 9, 2026
- 3 Stocks That May Be Undervalued In April 2026Yahoo Finance·Apr 9, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 8, 2026
- ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Omitted Inconsistent Trial Data: Levi & KorsinskyGlobeNewswire Inc.·Apr 6, 2026
- ADLX Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Aldeyra Therapeutics, Inc. Class Action LawsuitGlobeNewswire Inc.·Apr 6, 2026
- Aldeyra Therapeutics And 2 More Promising Penny Stocks For Your WatchlistYahoo Finance·Mar 25, 2026
- ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDAYahoo Finance·Mar 18, 2026
Price Data
Open$2.00
Previous Close$2.05
Day High$2.21
Day Low$2.00
52 Week High$6.17
52 Week Low$1.07
52-Week Range
$1.07$6.17
$2.02
Fundamentals
Market Cap$118M
P/E Ratio—
EPS$-0.45
Dividend Yield—
Dividend / Share—
ROE-51.8%
Profit Margin—
Debt / Equity—
Trading
Volume2.4M
Avg Volume (10D)—
Shares Outstanding60.3M
About Aldeyra The
Aldeyra Therapeutics, Inc., a biotechnology company, develops and markets drugs for immune-mediated systemic and eye diseases. The company is headquartered in Lexington, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—